Filter your search
- $895.00 – $1,790.00There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the […]October 1, 2004$3,500.00 – $7,000.00With an aging population in the United States, the incidence of prevalence of age-related diseases and disorders is expected to mount rapidly over the next decade. Since senior citizens already consume a disproportionate amount of healthcare dollars, the economic picture will only go from bad to worse insofar as healthcare is concerned. The solution to […]September 1, 2004$3,500.00 – $7,000.00Neural and muscular stimulation by electronic and magnetic means have evolved into a burgeoning product development and commercial fields. For decades, transcutaneous electronic nerve stimulation (TENS) has been a mainstay in the pain relief arsenal. Through the years, as biocompatibility problems were being solved, electrode and sensor implants developed into a multitude of technologies with […]September 1, 2004$895.00 – $1,790.00Nanotechnology is no longer a bench-top curiosity. It is becoming a real commercial force for a variety of applications. This market briefing discusses the state of play in the race to commercialize products and forecasts likely market scenarios. The briefing forecasts the market in generally promising areas such as cancer therapeutics, specialized drug delivery, diagnostics, […]September 1, 2004$1,995.00 – $5,990.00The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents […]August 1, 2004$3,500.00 – $7,000.00This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail. The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These […]August 1, 2004$995.00 – $1,910.00Blood banking has been the most dynamic testing segment to adopt molecular diagnostics approaches since their introduction. Screening for HIV, HCV and HBV in donated blood, plasma and organs has largely been done by immunoassay procedures. In conjunction with background screening, this has become a very effective approach toward guaranteeing the safety of the blood/organ […]August 1, 2004$895.00 – $1,790.00After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a […]August 1, 2004$895.00 – $1,790.00Alternative routes of administration for insulin has been one of the leading drivers of drug delivery industry. Although transdermal and transmucosal systems have shown promise and true oral delivery remains a goal, pulmonary delivery has emerged as the leading area of development. Several major players in the pharmaceutical industry have given their backing to inhaled […]July 1, 2004$3,500.00 – $7,000.00After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to […]July 1, 2004